Chromosome 1q21 gains confer inferior outcomes in multiple myeloma treated with bortezomib but copy number variation and percentage of plasma cells involved have no additional prognostic value
Gang An,
Yan Xu,
Lihui Shi,
Zhong Shizhen,
Shuhui Deng,
Zhenqing Xie,
Weiwei Sui,
Fenghuang Zhan,
Lugui Qiu
Affiliations
Gang An
Department of Lymphoma and Myeloma, Institute of Hematology and Blood Diseases Hospital, State Key Laboratory of Experimental Hematology, Chinese Academy of Medical Sciences and Peking Union of Medical College, Tianjin, China
Yan Xu
Department of Lymphoma and Myeloma, Institute of Hematology and Blood Diseases Hospital, State Key Laboratory of Experimental Hematology, Chinese Academy of Medical Sciences and Peking Union of Medical College, Tianjin, China
Lihui Shi
Department of Lymphoma and Myeloma, Institute of Hematology and Blood Diseases Hospital, State Key Laboratory of Experimental Hematology, Chinese Academy of Medical Sciences and Peking Union of Medical College, Tianjin, China
Zhong Shizhen
Department of Lymphoma and Myeloma, Institute of Hematology and Blood Diseases Hospital, State Key Laboratory of Experimental Hematology, Chinese Academy of Medical Sciences and Peking Union of Medical College, Tianjin, China
Shuhui Deng
Umbilical Cord Blood Bank of Tianjin, China
Zhenqing Xie
Department of Lymphoma and Myeloma, Institute of Hematology and Blood Diseases Hospital, State Key Laboratory of Experimental Hematology, Chinese Academy of Medical Sciences and Peking Union of Medical College, Tianjin, China
Weiwei Sui
Department of Lymphoma and Myeloma, Institute of Hematology and Blood Diseases Hospital, State Key Laboratory of Experimental Hematology, Chinese Academy of Medical Sciences and Peking Union of Medical College, Tianjin, China
Fenghuang Zhan
Department of Internal Medicine, Division of Hematology, Oncology, and Blood and Marrow Transplantation, University of Iowa, Iowa City, IA, USA
Lugui Qiu
Department of Lymphoma and Myeloma, Institute of Hematology and Blood Diseases Hospital, State Key Laboratory of Experimental Hematology, Chinese Academy of Medical Sciences and Peking Union of Medical College, Tianjin, China;Umbilical Cord Blood Bank of Tianjin, China
Chromosome 1q21 aberrations have not been yet been made part of routine clinical tests and their effect in multiple myeloma is still under investigation. The prognostic value of copy number variation and percentage of plasma cells involved have remained unclear. In the present study, we analyzed the prognostic value of 1q21 in a series of 290 cases of newly diagnosed multiple myeloma treated in a prospective, non-randomized clinical trial (BDH 2008/02). We found that incidence of 1q21 aberration increased at relapse, but its copy numbers and proportion of cells involved did not change. Gains of 1q21 had no impact on survival in patients receiving thalidomide-based treatment but conferred a significantly inferior prognosis in patients under bortezomib-based chemotherapy and was an independent adverse prognostic factor for progression free survival (HR 3.831; 95%CI: 2.125–6.907; P
